Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01429844




Registration number
NCT01429844
Ethics application status
Date submitted
5/09/2011
Date registered
7/09/2011
Date last updated
7/09/2011

Titles & IDs
Public title
Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation
Scientific title
Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients
Secondary ID [1] 0 0
EAILTx Tac vs. CsA in LuTx
Universal Trial Number (UTN)
Trial acronym
EAILTX
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bronchiolitis Obliterans 0 0
Immunosuppression 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tacrolimus
Treatment: Drugs - Cyclosporine

Active comparator: Tacrolimus - Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation

Active comparator: Cyclosporine - Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation


Treatment: Drugs: Tacrolimus
Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.

Treatment: Drugs: Cyclosporine
Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of bronchiolitis obliterans syndrome
Timepoint [1] 0 0
3 years post transplant
Secondary outcome [1] 0 0
Acute allograft rejection
Timepoint [1] 0 0
3 years post transplant
Secondary outcome [2] 0 0
Patient and graft survival
Timepoint [2] 0 0
3 years post transplant
Secondary outcome [3] 0 0
Incidence and spectrum of infections
Timepoint [3] 0 0
3 years post transplant
Secondary outcome [4] 0 0
Renal failure
Timepoint [4] 0 0
3 years post transplant
Secondary outcome [5] 0 0
Treatment failure
Timepoint [5] 0 0
3 years post transplant

Eligibility
Key inclusion criteria
* male or female recipients of a first heart-lung
* bilateral or single lung allograft suitable to receive triple immunosuppressive therapy with tacrolimus or cyclosporine, MMF and corticosteroids per standard guidelines
* Age range = 18-66 years
* Able to understand the purposes and risks of the study
* Female patients of child bearing age agreeing to maintain effective birth control practice during the follow-up period
Minimum age
18 Years
Maximum age
66 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* need for immunosuppressive regimen other than study medication or received additional organ transplantations
* Pregnant women, nursing mothers or women unwilling to use adequate contraception
* Serologic evidence of human immunodeficiency virus, hepatitis B surface antigen or hepatitis C virus antibodies
* Panresistant infections with Burkholderia cepacia or mycobacteria during the last 12 months preceding lung transplantation
* Patients with renal insufficiency (creatinine clearance < 40 ml/min
* Patients in need of invasive ventilator devices or extracorporeal membrane oxygenation

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2001
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2010
Sample size
Target
Accrual to date
Final
274
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
St. Vincent's Hospital - Sydney
Recruitment postcode(s) [1] 0 0
NSW 2010 - Sydney
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Wien
Country [2] 0 0
Belgium
State/province [2] 0 0
Bruxelles
Country [3] 0 0
Belgium
State/province [3] 0 0
Leuven
Country [4] 0 0
Germany
State/province [4] 0 0
Essen
Country [5] 0 0
Germany
State/province [5] 0 0
Hamburg
Country [6] 0 0
Germany
State/province [6] 0 0
Jena
Country [7] 0 0
Germany
State/province [7] 0 0
Kiel
Country [8] 0 0
Spain
State/province [8] 0 0
Barcelona
Country [9] 0 0
Spain
State/province [9] 0 0
Cordoba
Country [10] 0 0
Spain
State/province [10] 0 0
La Coruna
Country [11] 0 0
Spain
State/province [11] 0 0
Madrid
Country [12] 0 0
Spain
State/province [12] 0 0
Santander
Country [13] 0 0
Switzerland
State/province [13] 0 0
Lausanne

Funding & Sponsors
Primary sponsor type
Other
Name
Universitätsklinikum Hamburg-Eppendorf
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Hermann Reichenspurner, MD, PhD
Address 0 0
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01429844